KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

XANAX SR 0.5 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

0.5 MG

 

GENERIC NAME:

ALPRAZOLAM

 

MANUFACTURER:

PHARMACIA & UPJOHN

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

D

 

INDICATIONS:

Anxiety disorder, generalized

Panic disorder

 

SIDE EFFECTS:

emotional lability

fatigue

flushing

galactorrhea

gynecomastia

hepatic failure

hepatitis

hyperprolactinemia

hypersalivation

hyperventilation

hypoesthesia

hypotension

impaired cognition

irritability

libido decrease

libido increase

menstrual irregularity

physiological dependence

psychological dependence

Stevens-Johnson syndrome

teratogenesis

tolerance

tremor

weight gain

weight loss

withdrawal

xerostomia

agitation

akathisia

amnesia

anorexia

appetite stimulation

ataxia

confusion

constipation

depression

dizziness

drowsiness

dysuria

elevated hepatic enzymes

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

anxiety

benzodiazepine dependence

bipolar disorder

children

chronic obstructive pulmonary disease (COPD)

CNS depression

coma

dementia

depression

driving or operating machinery

elderly

hepatic disease

infants

labor

mania

myasthenia gravis

neonates

obesity

Parkinson's disease

porphyria

pregnancy

psychosis

pulmonary disease

renal failure

renal impairment

respiratory depression

seizure disorder

seizures

shock

sleep apnea

status epilepticus

substance abuse

 

ADULT DOSE:

Antianxiety agent-Oral, initially 250 to 500 mcg (0.25 to 0.5 mg) three times a day, the dosage being titrated to the needs of the patient up to a maximum total dose of 4 mg per day . Note: Debilitated patients-Oral, initially 250 mcg (0.25 mg) two or three times a day, the dosage being increased as needed and tolerated . The starting dosage may be decreased if adverse effects occur . Antipanic agent-Oral, initially 500 mcg (0.5 mg) three times a day, the dosage being increased as needed and tolerated up to a maximum of 10 mg per day .

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Antianxiety or antipanic agent-Children younger than 18 years of age: Safety and efficacy have not been established . 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Antianxiety agent-Oral, initially 250 mcg (0.25 mg) two or three times a day, the dosage being increased as needed and tolerated .

 

 

PREVIOUS

  

NEXT